The Performance of Nesfatin-1 in Distinguishing Irritable Bowel Syndrome Presenting Predominantly with Diarrhea from Celiac Disease

Karatay, Eylem; Gül-Utku, Özlem; Aksoy, Neval

doi:10.7754/clin.lab.2020.191215

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nucleobindin-2 (NUCB2)/Nesfatin-1 is a multifunctional biomolecule, which plays an important role in the diagnosis and treatment of numerous diseases [6][7][8][9]. The in-depth study of NUCB2/Nesfatin-1 has shown its close relationship to IBS [10][11][12]. Our previous study showed that various NUCB2/Nesfatin-1 concentration gradients differ-ently regulated visceral hypersensitivity in IBS [13].…”

Section: Introductionmentioning

confidence: 99%

NUCB2/Nesfatin-1 Regulation of Chronic Visceral Hyperalgesia

Yuan

et al. 2022

Applied Bionics and Biomechanics

View full text Add to dashboard Cite

Objective. We previously described that different concentration Nucleobindin-2 (NUCB2)/Nesfatin-1 gradients differently regulated visceral hypersensitivity in irritable bowel syndrome. Therefore, this study is aimed at evaluating the effect of NUCB2/Nesfatin-1 on model rats with chronic visceral hyperalgesia. Methods. Neonatal and mature Sprague-Dawley rats were randomly divided into the healthy control and chronic visceral hyperalgesia model groups. The model was built by combining maternal separation with the acetic acid enema. The models were identified by the distension volume threshold to reach abdominal withdraw reflex AWR score = 3 , histological staining, and myeloperoxidase (MPO) detection. The visceral sensitivity to chronic visceral hyperalgesia was then evaluated. Result. Rats in the model group responded more strongly to pulling stimulation than healthy controls; the distension volume threshold causing AWR3 response in model rats was lower than the control group before NUCB2/Nesfatin-1 intervention. After intervention, the distension volume threshold was significantly lower in the NUCB2/Nesfatin-1 central intervention group than in the NUCB2/Nesfatin-1 peripheral intervention group, and the peak value of external oblique muscle electrical activity was significantly higher. Additionally, compared with the male intervention group, in the female intervention group, the volume threshold was significantly lower and the peak value was higher. Conclusion. NUCB2/Nesfatin-1 could regulate visceral sensitivity in chronic visceral hyperalgesia model rats; its regulatory effect correlated with the type of NUCB2/Nesfatin-1 intervention approaches (central or peripheral) and sex (male or female).

show abstract

Section: Introductionmentioning

confidence: 99%

NUCB2/Nesfatin-1 Regulation of Chronic Visceral Hyperalgesia

Yuan

et al. 2022

Applied Bionics and Biomechanics

View full text Add to dashboard Cite

show abstract

“…Another study conducted by Buzcu et al[ 12 ] based on the acute pancreatitis model showed that Nesfatin-1 has anti-inflammatory effects on acute pancreatitis, basically affecting melanocortin receptors. In another study conducted by Karatay et al,[ 13 ] the performance of Nesfatin-1 in separating celiac disease and diarrhea-weighted irritable bowel syndrome, which is an inflammatory disease, was investigated, and significantly higher Nesfatin-1 levels were detected in cases with Celiac Disease.…”

Section: Discussionmentioning

confidence: 99%

“…[9,10] There are many studies in the literature reporting that Nesfatin-1 has pro-inflammatory or anti-inflammatory functions. [11][12][13][14] However, although there are publications, which show that there is a relation between Nesfatin-1 and inflammatory events, there is no study showing its relations with acute cholecystitis, or examining its use in the diagnosis and staging of acute cholecystitis.…”

Section: Introductionmentioning

confidence: 99%

Prognostic effect of Nesfatin-1 on the diagnosis and staging of acute cholecystitis

Tekin¹

2021

Ulus Travma Acil Cerrahi Derg

View full text Add to dashboard Cite

BACKGROUND: Gallbladder diseases are an important health concern affecting approximately 20% of the population in developed countries. Acute cholecystitis is the most common complication of gallstones. The aim of our study is to determine the use of Nesfatin-1, which is an easily applicable and fast resulting and is thought to have an association with inflammatory events, in the diagnosis and grading of acute cholecystitis. METHODS: Patients who admitted and were hospitalized and treated with the acute cholecystitis diagnosis in İstanbul Training and Research Hospital between July 1, 2020, and December 1, 2020, were included in the study. The patients were divided in threemain groups as mild, moderate, and severe according to Tokyo Guidelines 2018 based on their routine blood tests and imaging results. All patients who are included in the study were tested for their blood leukocyte, neutrophil, lymphocyte, Nesfatin-1 levels, and neutrophil/lymphocyte ratios within the first 24 h of their hospitalization. RESULTS: With at least 15 patients in each group, 61 volunteers in total were included in the study as healthy volunteers, mild, moderate, and severe cholecystitis. The average age of the participants were 58.11±19.76 years. About 47.54% of the participants were female and 52.46% weremale. In the study, Nesfatin-1 levels in the patient groups were found to be lower than the control group. In the subgroup analyzes, Nesfatin-1 values in the middle patient group were found to be significantly lower than the control group; however, there was no statistically significant relationship between the severity of the disease and Nesfatin-1. CONCLUSION: Nesfatin-1 may guide the clinician for the diagnosis of the disease; however, no significant relationship was found between Nesfatin-1 and the severity or stage of the disease.

show abstract

The Performance of Nesfatin-1 in Distinguishing Irritable Bowel Syndrome Presenting Predominantly with Diarrhea from Celiac Disease

Cited by 2 publications

References 0 publications

NUCB2/Nesfatin-1 Regulation of Chronic Visceral Hyperalgesia

NUCB2/Nesfatin-1 Regulation of Chronic Visceral Hyperalgesia

Prognostic effect of Nesfatin-1 on the diagnosis and staging of acute cholecystitis

Contact Info

Product

Resources

About